REFERENCES

1. Trends G. Public health and aging: trends in aging - United States and worldwide. JAMA 2003;289:1371-3.

2. Lakatta EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev 2002;7:29-49.

3. Spadaro O, Youm Y, Shchukina I, et al. Caloric restriction in humans reveals immunometabolic regulators of health span. Science 2022;375:671-7.

4. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009;1791:327-38.

5. Jiang D, Zheng D, Wang L, et al. Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females. PLoS One 2013;8:e59752.

6. Speakman JR, Mitchell SE. Caloric restriction. Mol Aspects Med 2011;32:159-221.

7. de Almeida AJPO, Ribeiro TP, de Medeiros IA. Aging: molecular pathways and implications on the cardiovascular system. Oxid Med Cell Longev 2017;2017:7941563.

8. Martel J, Chang SH, Wu CY, et al. Recent advances in the field of caloric restriction mimetics and anti-aging molecules. Ageing Res Rev 2021;66:101240.

9. Kristan DM. Calorie restriction and susceptibility to intact pathogens. Age (Dordr) 2008;30:147-56.

10. Goldberg EL, Romero-Aleshire MJ, Renkema KR, et al. Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms. Aging Cell 2015;14:130-8.

11. Kraus WE, Bhapkar M, Huffman KM, et al. 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:673-83.

12. Garg SK, Delaney C, Shi H, Yung R. Changes in adipose tissue macrophages and T cells during aging. Crit Rev Immunol 2014;34:1-14.

13. Ferguson JF, Hinkle CC, Mehta NN, et al. Translational studies of lipoprotein-associated phospholipase A2 in inflammation and atherosclerosis. J Am Coll Cardiol 2012;59:764-72.

14. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374:549-53.

15. White HD, Held C, Stewart R, et al. STABILITY Investigators. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702-11.

16. Lv SL, Zeng ZF, Gan WQ, et al. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation. Acta Pharmacol Sin 2021;42:2016-32.

17. Sokolova M, Yang K, Hansen SH, et al. NLRP3 inflammasome deficiency attenuates metabolic disturbances involving alterations in the gut microbial profile in mice exposed to high fat diet. Sci Rep 2020;10:21006.

18. Ma Y, Mouton AJ, Lindsey ML. Cardiac macrophage biology in the steady-state heart, the aging heart, and following myocardial infarction. Transl Res 2018;191:15-28.

19. Siddiqui MK, Smith G, St Jean P, et al. Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events. Diabetologia 2022;65:101-12.

The Journal of Cardiovascular Aging

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/